Eisai Co., Ltd.

Eisai Co., Ltd.

ESALF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$9.32B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Eisai Co., Ltd.Eisai Co., Ltd.33.33.09%5%-0.3

Earnings Call Q3 2026

February 9, 2026 - AI Summary

Strong Q3 performance, driven almost entirely by organic growth (record Q3 revenue) - Revenue: JPY 619.9bn, +3.1% YoY (CFO emphasized it was a record high third-quarter). - Operating profit (OP): JPY 54.5bn, down YoY mainly due to absence of temporary/onetime profit from out-licensing this fiscal year. - “Good news”: CFO/COO both stressed OP is increasingly supported by organic business—organic profit contribution roughly doubled vs. prior year’s same period. - Margin dynamics: gross margin largely stable; cost of sales ratio 22.5% slightly higher (explained by mix changes and prior-year out-licensing gains that don’t recur).
Full-year forecast maintained (despite uncertainties), with Q4 cost headwinds - Company maintains guidance for FY2025: - Revenue: JPY 790bn - Operating profit: JPY 54.5bn - CFO highlighted Q4 spending plans and costs not fully reflected yet: - Structural reform costs in EMEA (expected in Q4). - Additional R&D allocation to next-generation key programs (e.g., anti-Tau antibody etalanetug, narcolepsy E2086). - Risk/uncertainty: revenue side includes potential volatility from partnership/out-licensing “one-time” items; management is intentionally not increasing guidance due to this.
“3Ls” momentum—3 flagship products underpin growth - Lenvima: JPY 258.1bn revenue, +4% YoY; growth across regions, with U.S. impact from IRA largely absorbed by demand. - DAYVIGO: JPY 47.7bn, +18% YoY; Japan absorbed a 14% drug price reduction yet delivered growth; management is confident about FY forecast of JPY 58bn. - LEQEMBI: JPY 61.8bn through first 3 quarters, +109% YoY (more than doubling). - Continued region-by-region strength: U.S., Japan, China, EMEA all growing (with China highlighted as accelerating access, including private market).

Exclusive for Stockcircle Pro members

Sign upSign Up
$17.85

Current Fair Value

46% downside

Overvalued by 46% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$9.32 Billion
Enterprise Value$-53,203,716,600.00
Annual dividend$1.01
Dividend yield3.09%
Earnings per Share$137.41
Beta-0.05
Outstanding Shares281,890,000

Return

Return on Equity4.89%ROE
Return on Assets2.88%
Return on Invested Capital5.12%

Valuation & Multiples

P/E Ratio33.34P/E Ratio
PEG220.41PEG
Price to Sales0.01Price to Sales
Price to Book Ratio0.01Price to Book Ratio
Enterprise Value to Revenue1.56
Enterprise Value to EBIT23.72
Enterprise Value to Net Income-2
Total Debt to Enterprise0.18
Debt to Equity0.28Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 10, 2026
EPS
$0.26
Est. $0.37
Revenue
$1.50 B
Est. $1.40 B

Next Earnings Call

Expected Date
February 10, 2027
EPS Estimate
$0.45
Consensus analyst estimate
Revenue Estimate
$1.51 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Eisai Co Ltd

10,543 employees
CEO: Haruo Naito

Eisai Co., Ltd. is a Japanese pharmaceutical firm that develops, manufactures, and markets a broad spectrum of medical and healthcare products. Its significant therapeutic contributions include Aricept, prescribed for individuals with Al...